Silexion Therapeutics Corp.

Biotechnology • Healthcare • Jerusalem, Israel • SLXNW (NCM)

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

972 2 674 3430 The Goldyne Savad Inst. of Gene Therapy, Israel

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets

TradingView — Track All Markets • Jan 6

Silexion Therapeutics Announces 1-for-15 Reverse Share Split - Yahoo Finance

Yahoo Finance • Jul 16

Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative

Quiver Quantitative • Dec 16

Silexion Therapeutics stock falls after warrant exercise deal - Investing.com

Investing.com • Aug 1

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering - GlobeNewswire

GlobeNewswire • Sep 11

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Silexion Therapeutics Corp had layoffs?

No layoff events have been recorded for Silexion Therapeutics Corp in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Silexion Therapeutics Corp have?

Silexion Therapeutics Corp has approximately 11 employees.

What industry is Silexion Therapeutics Corp in?

Silexion Therapeutics Corp operates in the Biotechnology industry, within the Healthcare sector.

Is Silexion Therapeutics Corp a publicly traded company?

Yes, Silexion Therapeutics Corp is publicly traded under the ticker symbol SLXNW on the NCM.

Where is Silexion Therapeutics Corp headquartered?

Silexion Therapeutics Corp is headquartered in Jerusalem, Israel at The Goldyne Savad Inst. of Gene Therapy, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.